________________________________________________________
________________________________________________________
Precise method to transform investing.
The traditional process of investing in drugs is buttoned down.
Established venture capitalists overlook drugs from startups that are located outside bioscience hubs. Government agencies are slow to invest. And young firms that lack experience struggle to turn lab success into clinical breakthroughs.
Cancer Focus Fund stands apart because of how we choose drugs.
We are agnostic about where the therapies are originally developed. We scour the globe in search of the most intriguing oncology assets, and we have the right of first offer to review certain pre-IND and IND-stage therapies being considered for clinical studies at MD Anderson.
Key experts at MD Anderson lead our Scientific Advisory Committee, which meets quarterly to review the drugs and narrow the candidates to a select few that are using a novel approach to take on cancer.
Cancer Focus Fund managers then conduct due diligence. They review market potential, patentability, competition and, most importantly, the management team's ability to advance the drugs through clinical trials to regulatory approval and, ultimately, to the patient.
Our other strategic partners - Ochsner MD Anderson Cancer Center in New Orleans and LSU Feist-Weiller Cancer Center in Shreveport - provide our portfolio companies additional locations for trials.
Our investments are exchanged for equity and downstream economics based on the regulatory and clinical success of the assets in which we invest.
